(NHC) National HealthCare - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE MKT (USA) | Market Cap: 3.047m USD | Total Return: 85.5% in 12m
Avg Turnover: 17.7M
EPS Trend: 83.0%
Rev. Trend: 98.4%
Warnings
No concerns identified
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind, Pullback 52w
National HealthCare Corporation (NHC) is a diversified healthcare provider specializing in post-acute care and senior living services. The company operates through two primary segments: Inpatient services, which include skilled nursing, assisted living, and behavioral health facilities, and Homecare and Hospice services. Founded in 1971, NHC also provides ancillary services such as pharmacy operations, managed care insurance, and property leasing to third-party operators.
The skilled nursing sector relies heavily on government reimbursement programs, with Medicare and Medicaid typically accounting for a significant portion of industry revenue. NHC utilizes a vertically integrated business model by offering a continuum of care that allows patients to transition between intensive rehabilitative therapy and home-based medical assistance within the same provider network.
Investors should examine the historical performance data available on ValueRay to better understand the companys valuation. This Tennessee-based firm remains a prominent mid-cap player in the health care facilities sub-industry.
- Medicare and Medicaid reimbursement rate adjustments impact inpatient segment margins
- Skilled nursing occupancy rates drive core revenue growth and operating leverage
- Expansion of homecare and hospice services diversifies revenue away from facilities
- Labor cost inflation and nursing shortages pressure long-term care profitability
| Net Income: 123.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.74 > 1.0 |
| NWC/Revenue: 12.84% < 20% (prev 15.71%; Δ -2.87% < -1%) |
| CFO/TA 0.14 > 3% & CFO 208.4m > Net Income 123.7m |
| Net Debt (-272.3m) to EBITDA (213.6m): -1.27 < 3 |
| Current Ratio: 1.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (15.8m) vs 12m ago 1.25% < -2% |
| Gross Margin: 37.21% > 18% (prev 0.38%; Δ 3.68k% > 0.5%) |
| Asset Turnover: 99.20% > 50% (prev 88.74%; Δ 10.45% > 0%) |
| Interest Coverage Ratio: 37.07 > 6 (EBITDA TTM 213.6m / Interest Expense TTM 4.53m) |
| A: 0.13 (Total Current Assets 449.3m - Total Current Liabilities 253.6m) / Total Assets 1.52b |
| B: 0.56 (Retained Earnings 858.9m / Total Assets 1.52b) |
| C: 0.11 (EBIT TTM 168.1m / Avg Total Assets 1.54b) |
| D: 2.01 (Book Value of Equity 857.3m / Total Liabilities 427.5m) |
| Altman-Z'' = 5.52 = AAA |
| DSRI: 0.87 (Receivables 137.7m/142.2m, Revenue 1.52b/1.37b) |
| GMI: 1.01 (GM 37.21% / 37.73%) |
| AQI: 1.07 (AQ_t 0.24 / AQ_t-1 0.22) |
| SGI: 1.11 (Revenue 1.52b / 1.37b) |
| TATA: -0.06 (NI 123.7m - CFO 208.4m) / TA 1.52b) |
| Beneish M = -3.05 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at USD 190.00 with a total of 167,406 shares traded.
Over the past week, the price has changed by -3.21%,
over one month by +7.72%,
over three months by +19.09% and
over the past year by +85.54%.
National HealthCare has no consensus analysts rating.
| Analysts Target Price | 6.2 | -96.8% |
P/E Trailing = 24.7563
P/E Forward = 9.8912
P/S = 1.9969
P/B = 2.8062
P/EG = 0.8241
Revenue TTM = 1.52b USD
EBIT TTM = 168.1m USD
EBITDA TTM = 213.6m USD
Long Term Debt = 32.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 26.0m USD (from shortTermDebt, last quarter)
Debt = 39.3m USD (from shortLongTermDebtTotal, last quarter) (leases 39.3m already included)
Net Debt = -272.3m USD (calculated: Debt 39.3m - CCE 311.6m)
Enterprise Value = 2.77b USD (3.05b + Debt 39.3m - CCE 311.6m)
Interest Coverage Ratio = 37.07 (Ebit TTM 168.1m / Interest Expense TTM 4.53m)
EV/FCF = 20.34x (Enterprise Value 2.77b / FCF TTM 136.4m)
FCF Yield = 4.92% (FCF TTM 136.4m / Enterprise Value 2.77b)
FCF Margin = 8.95% (FCF TTM 136.4m / Revenue TTM 1.52b)
Net Margin = 8.11% (Net Income TTM 123.7m / Revenue TTM 1.52b)
Gross Margin = 37.21% ((Revenue TTM 1.52b - Cost of Revenue TTM 957.1m) / Revenue TTM)
Gross Margin QoQ = 30.51% (prev 39.66%)
Tobins Q-Ratio = 1.82 (Enterprise Value 2.77b / Total Assets 1.52b)
Interest Expense / Debt = 11.53% (Interest Expense 4.53m / Debt 39.3m)
Taxrate = 19.44% (8.71m / 44.8m)
NOPAT = 135.4m (EBIT 168.1m * (1 - 19.44%))
Current Ratio = 1.63 (Total Current Assets 449.3m / Total Current Liabilities 275.0m)
Debt / Equity = 0.04 (Debt 39.3m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = -1.27 (Net Debt -272.3m / EBITDA 213.6m)
Debt / FCF = -2.00 (Net Debt -272.3m / FCF TTM 136.4m)
Total Stockholder Equity = 1.06b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.05% (Net Income 123.7m / Total Assets 1.52b)
RoE = 11.68% (Net Income TTM 123.7m / Total Stockholder Equity 1.06b)
RoCE = 15.40% (EBIT 168.1m / Capital Employed (Equity 1.06b + L.T.Debt 32.5m))
RoIC = 9.25% (NOPAT 135.4m / Invested Capital 1.46b)
WACC = 8.60% (E(3.05b)/V(3.09b) * Re(8.59%) + D(39.3m)/V(3.09b) * Rd(11.53%) * (1-Tc(0.19)))
Discount Rate = 8.59% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 0.81%
[DCF] Terminal Value 75.50% ; FCFF base≈132.7m ; Y1≈141.3m ; Y5≈168.2m
[DCF] Fair Price = 176.1 (EV 2.48b - Net Debt -272.3m = Equity 2.75b / Shares 15.6m; r=8.60% [WACC]; 5y FCF grow 7.26% → 2.50% )
EPS Correlation: 83.01 | EPS CAGR: 46.60% | SUE: N/A | # QB: 0
Revenue Correlation: 98.38 | Revenue CAGR: 15.19% | SUE: N/A | # QB: 0